---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-005118"
form_type: "8-K"
ticker: "CNSP"
cik: "0001729427"
company_name: "CNS Pharmaceuticals, Inc."
filed_at: "2024-07-30T23:59:59+00:00"
generated_at: "2026-05-31T15:21:53.228306+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CNS Pharmaceuticals in-licenses TPI 287 from Cortice for brain cancer treatment

## Summary
- CNS Pharmaceuticals entered an exclusive license agreement with Cortice Biosciences for TPI 287, a blood-brain barrier permeable abeotaxane, covering U.S., Canada, Mexico, and Japan.
- Upfront consideration includes 616,698 shares of CNS common stock; future milestone payments up to $100M in cash or shares, plus royalties of 3.0%-7.5%.
- TPI 287 showed 60% objective response rate and 13.4 months overall survival in a Phase 1 trial with bevacizumab in recurrent GBM.
- Company plans to engage FDA in 2025 for a potential registration study of TPI 287 in recurrent glioblastoma.
- Topline results from Berubicin pivotal trial expected in first half of 2025; TPI 287 will leverage existing clinical infrastructure.

## SEC filing metadata
- accession: 0001683168-24-005118
- form_type: 8-K
- ticker: CNSP
- cik: 0001729427
- company_name: CNS Pharmaceuticals, Inc.
- filed_at: 2024-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005118/0001683168-24-005118-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729427/000168316824005118/cns_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-005118
- JSON: https://secwatch.observer/filing/0001683168-24-005118.json
- Plain text: https://secwatch.observer/filing/0001683168-24-005118.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.